The Biopharmaceutical Giant: Amicus Therapeutics

Amicus Therapeutics is a Biopharmaceutical Company founded on February 2nd, 2002.The biotechnological company is located in Cranbury New Jersey in the United States. Amicus Therapeutics became a publicly owned company in 2007 withdrawing from its funding by Canaan Partners, Radius Ventures and New Enterprise Associates. The primary focus of Amicus Therapeutics is the provision of therapies and treatments for orphan and common diseases which come in the form of unique genetic disorders among other forms. These rare diseases are collectively called lysosomal storage disorders.

 

John F. Crowley is the CEO OF Amicus Therapeutics having succeeded Donald Hayden in 2010.Since then Hayden remained a close associate of Amicus Therapeutics (WeeklyOpinion). Other important stakeholders of the company are Bradley L. Campbell and William D. Baird 111 as chief financial officer. In the year 2014 Amicus Therapeutics became recognized worldwide for having the most extensive portfolio of pharmacological chaperones that are small.

 

Amicus Therapeutics widely bases the development of its products on the Chaperone-Advanced Replacement Therapy (https://www.crunchbase.com/organization/amicus-therapeutics). Migalastat is Amicus Therapeutics’ most advanced pharmacological chaperone that is used in the treatment of Fabry disease. Migalastat in the treatment of Fabry disease is used concerning the special and unique genetic diagnosis. In a bid to help in the overall management of lysosomal diseases Amicus Therapeutics is in the advanced stages of developing a therapy for Epidermylosis Bullosa which is a connective tissue disorder.

 

In partnership with JCR Pharmaceutical and GlaxoSmithKline for the past three years Amicus Therapeutics, have been working to investigate further on the causes and effects of lysosomal storage disorders. As far as collaborations are concerned, Amicus Therapeutics has had its share of failures, for example, the untimely cancellation of its collaboration with The Shire. This cancellation of partnership led to the opening of the company as a public company due to financial strains. Amicus Therapeutics relies on manufacturing contracts as it does not have its manufacturing plants.

 

Over the years the company has grown despite setbacks related to partnerships. It has expanded its research site to San Diego. Amicus Therapeutics took over ownership of one of its main competitors the Callidus Biopharma.